Comparative Evaluation of Vitek 2 and Etest versus Broth Microdilution for Ceftazidime/Avibactam and Ceftolozane/Tazobactam Susceptibility Testing of

BMD antimicrobial susceptibility testing carbapenem-resistant Enterobacterales carbapenem-resistant Pseudomonas challenge isolates major error very major error

Journal

Antibiotics (Basel, Switzerland)
ISSN: 2079-6382
Titre abrégé: Antibiotics (Basel)
Pays: Switzerland
ID NLM: 101637404

Informations de publication

Date de publication:
27 Jun 2022
Historique:
received: 17 05 2022
revised: 16 06 2022
accepted: 24 06 2022
entrez: 27 7 2022
pubmed: 28 7 2022
medline: 28 7 2022
Statut: epublish

Résumé

Ceftazidime/avibactam (CZA) and ceftolozane/tazobactam (C/T) are novel antibiotics with activity against multidrug-resistant Gram-negative pathogens. Nevertheless, resistance to both agents has been reported emphasizing the need for accurate and widely accessible susceptibility testing. In the present study, Vitek 2 and Etest CAZ and C/T MIC results for 100 non-repetitive clinical isolates (83

Identifiants

pubmed: 35884118
pii: antibiotics11070865
doi: 10.3390/antibiotics11070865
pmc: PMC9312067
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Front Microbiol. 2021 Sep 16;12:710526
pubmed: 34603236
Drugs. 2018 Apr;78(6):675-692
pubmed: 29671219
Clin Infect Dis. 2016 Jul 1;63(1):83-8
pubmed: 27025822
Lancet. 2022 Feb 12;399(10325):629-655
pubmed: 35065702
Infection. 2018 Apr;46(2):165-181
pubmed: 29110143
J Antimicrob Chemother. 2018 Apr 1;73(4):909-915
pubmed: 29365094
Antibiotics (Basel). 2021 Apr 10;10(4):
pubmed: 33920199
Med Sci (Basel). 2017 Dec 21;6(1):
pubmed: 29267233
J Clin Med. 2021 Mar 04;10(5):
pubmed: 33806604
Nat Rev Microbiol. 2019 Jan;17(1):3
pubmed: 30467331
Clin Infect Dis. 2017 Jul 1;65(1):158-161
pubmed: 28329350
Int J Antimicrob Agents. 2019 Apr;53(4):408-415
pubmed: 30415002
Infect Dis Clin North Am. 2020 Dec;34(4):773-819
pubmed: 33011051
J Antimicrob Chemother. 2021 Sep 15;76(10):2586-2592
pubmed: 34245282
JAC Antimicrob Resist. 2021 Jul 16;3(3):dlab092
pubmed: 34286272
J Clin Microbiol. 2018 Aug 27;56(9):
pubmed: 29976590
J Clin Microbiol. 2018 Jan 24;56(2):
pubmed: 29167294
J Clin Microbiol. 2018 Aug 27;56(9):
pubmed: 29899002
Int J Antimicrob Agents. 2019 Aug;54(2):255-260
pubmed: 31071465
J Clin Microbiol. 2021 Feb 18;59(3):
pubmed: 33268536
Lancet Infect Dis. 2018 Mar;18(3):318-327
pubmed: 29276051
Euro Surveill. 2018 Nov;23(46):
pubmed: 30458912
Infect Dis Ther. 2021 Dec;10(4):1989-2034
pubmed: 34379310
J Clin Microbiol. 2018 Feb 22;56(3):
pubmed: 29212704
Front Med (Lausanne). 2019 Apr 16;6:74
pubmed: 31041313
Lancet Infect Dis. 2019 Dec;19(12):1299-1311
pubmed: 31563344
BMC Microbiol. 2020 Jun 29;20(1):187
pubmed: 32600252

Auteurs

Arhodoula Papadomanolaki (A)

Laboratory of Clinical Microbiology, "Attikon" University Hospital, Medical School, National and Kapodistrian University of Athens, 12462 Athens, Greece.

Maria Siopi (M)

Laboratory of Clinical Microbiology, "Attikon" University Hospital, Medical School, National and Kapodistrian University of Athens, 12462 Athens, Greece.

Polyxeni Karakosta (P)

Laboratory of Clinical Microbiology, "Attikon" University Hospital, Medical School, National and Kapodistrian University of Athens, 12462 Athens, Greece.

Sophia Vourli (S)

Laboratory of Clinical Microbiology, "Attikon" University Hospital, Medical School, National and Kapodistrian University of Athens, 12462 Athens, Greece.

Spyros Pournaras (S)

Laboratory of Clinical Microbiology, "Attikon" University Hospital, Medical School, National and Kapodistrian University of Athens, 12462 Athens, Greece.

Classifications MeSH